REG - Haleon PLC Haleon Netherlands Haleon UK Capital - EMTN programme publication of listing particulars

HALEONAnnouncement

07/05/2025 17:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250507:nRSG7564Ha&default-theme=true

RNS Number : 7564H  Haleon PLC  07 May 2025

 

 

Haleon plc: EMTN programme publication of listing particulars

 

07 May 2025: Haleon plc (the "Company" or "Haleon") today announces that,
following a routine annual update, listing particulars dated 7 May 2025
regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s
£10,000,000,000 Euro Medium Term Note ("EMTN") Programme, guaranteed by the
Company, have been published (the "Listing Particulars").

 

A copy of the Listing Particulars is available for inspection at and can be
downloaded from www.haleon.com/investors/debt-investors.

 

Amanda Mellor

Company Secretary

 

Enquiries

 

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman     +44 7894 505730
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

Disclaimer

Please note that the information contained in the Listing Particulars may be
addressed to and/or targeted at persons who are residents of particular
countries (specified in the Listing Particulars) only and is not intended for
use and should not be relied upon by any person outside these countries and/or
to whom the offer contained in the Listing Particulars is not addressed. Prior
to relying on the information contained in the Listing Particulars, you must
ascertain from the Listing Particulars whether or not you are part of the
intended addressees of the information contained in the Listing Particulars.

 

Your right to access this service is conditional upon complying with the above
requirement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PDIEASSXELDSEFA